Research Insights

A recent breakthrough from researchers at Biohub and UC Berkeley demonstrates exactly that. Their development of a laser phase plate significantly enhances the contrast of cryo-electron microscopy (cryo-EM), allowing scientists to visualize proteins and cellular structures that were previously difficult—or even impossible—to observe. Why does this matter beyond microscopy? Because every advancement in biological measurement improves the quality of the data we generate. And in

With the introduction of Claude Science, Anthropic has signaled something profound: frontier AI companies increasingly see biology—not just software—as the next frontier for innovation. Beyond launching an AI workbench tailored for scientific research, Anthropic has also announced plans to pursue drug discovery for neglected diseases, marking a shift from building AI tools to actively participating in therapeutic discovery. This reflects a broader transformation in our indust

The U.S. Food and Drug Administration (FDA) has released a draft guidance recommending the use of Quantitative Systems Pharmacology (QSP) modeling to inform first-in-human dose selection. This represents another important step toward modernizing drug development by integrating computational science into regulatory decision-making and reducing unnecessary reliance on animal studies. For the rare disease community, this development is particularly significant. Traditional drug

The process of discovering new medicines has traditionally been long, costly, and uncertain. Developing a single drug can take over a decade and billions of dollars, with many candidates failing in late stages. Today, AI powered drug discovery techniques are transforming this landscape by speeding up research, reducing costs, and improving the chances of success. This shift is opening new possibilities for treating diseases that were once considered untreatable. AI software a